DGAP-News: WILEX AG: WILEX Inc. appoints Walter Carney as CSO for the further development of Oncogene Science diagnostics
(firmenpresse) - DGAP-News: WILEX AG / Key word(s): Change of Personnel
WILEX AG: WILEX Inc. appoints Walter Carney as CSO for the further
development of Oncogene Science diagnostics
15.02.2012 / 07:07
---------------------------------------------------------------------
PRESS RELEASE
WILEX Inc. appoints Walter Carney as CSO for the further development of
Oncogene Science diagnostics
Cambridge, MA, USA, and Munich, Germany, 15 February 2012. WILEX Inc., a
wholly owned US subsidiary of WILEX AG (ISIN DE0006614720 / WL6 / FSE),
today announced that Walter Carney, Ph.D., has joined the company as Chief
Scientific Officer (CSO).
Professor Olaf G. Wilhelm, Chief Executive Officer of WILEX Inc. and WILEX
AG commented: 'We have known Walt for many years from our cooperation with
Oncogene Science during the Bayer and Siemens times. As the previous CEO of
Oncogene Science, Dr. Carney managed all aspects of the scientific and
business operations. His network and his experience in developing
diagnostic tests make him an invaluable member of our team'.
'I am very excited to be back on board with the Oncogene Science team - now
within the new WILEX Group. WILEX is a proven pioneer in the field of
personalized medicine and focused cancer therapies. I am convinced we are
now in the position to revolutionize the way cancer treatment decisions are
made today and tomorrow' said Dr. Carney.
Dr. Carney worked with Oncogene Science for nearly 20 years - initially at
OSI Pharmaceuticals and then as part of Bayer HealthCare and finally as a
unit of Siemens Healthcare Diagnostics. Prior to WILEX's acquisition of
Oncogene Science from Siemens, Dr. Carney joined On-Q-ity as CSO and
Interim President. He was the first to discover and patent the circulating
extracellular domain for HER-2/neu, which is currently used in the
management of metastatic breast cancer and he discovered and patented
monoclonal antibodies to the family of ras oncoprotein mutations. He has
published over 250 articles and abstracts and holds more than 30 patents in
diagnostics. Dr. Carney is currently an active member in various renowned
oncological associations and serves as Assistant Clinical Professor,
Department of Pathology at the Tufts Medical Center in Boston.
About WILEX Inc.
WILEX Inc. is a wholly owned US subsidiary of WILEX AG and manufactures,
markets and sells diagnostic tests in oncology under the brand name
Oncogene Science. The product portfolio includes Enzyme-linked
ImmunoSorbent Assays (ELISA) and immunohistochemical (IHC) assays. With the
aim of supporting treatment regimens for cancer patients worldwide WILEX
Inc. offers biomarker tests for measuring oncogenes, growth factor
receptors (HER-2/neu, EGFr), proteases and protease inhibitors (uPA, PAI-1,
TIMP-1), as well as markers of hypoxia (CA IX). In addition to the new CA
IX IHC test WILEX Inc. provides the only FDA-cleared IVD ELISA that
quantifies the serum HER-2/neu level for the management and monitoring of
patient care for women with metastatic breast cancer. More information is
available on www.oncogene.com.
About WILEX AG
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused
on oncology, the company has a broad portfolio of near-to-market
therapeutic and diagnostic products for the targeted treatment and specific
detection of various types of cancer. The company's therapeutic product
candidatesare based on antibodies and small molecules. Through its US
subsidiary WILEX Inc. in Cambridge, MA, USA, WILEX markets a portfolio of
research use only and in vitro diagnostic tests under the brand Oncogene
Science. These diagnostic tests could be developed as companion diagnostics
in clinical trials and for therapy monitoring. The wholly owned subsidiary
Heidelberg Pharma GmbH, Ladenburg, Germany, gives WILEX access to an
attractive and highly promising antibody drug conjugate technology platform
and a pre-clinical service business. The business model of WILEX covers the
entire value chain in the oncology market and comprises research,
technology, development collaboration as well as sales and marketing.
WILEX' customers and partners include leading international pharmaceutical
companies. Website: www.wilex.com, ISIN DE0006614720 / WKN 661472 / Symbol
WL6.
Contact Press
WILEX AG
Corporate Communications
Katja Arnold (CIRO)
Grillparzerstr. 10
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
E-Mail: investors(at)wilex.com
This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will' 'should' 'future', 'potential' or similar expressions or by a
general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.
End of Corporate News
---------------------------------------------------------------------
15.02.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info(at)wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
156722 15.02.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 15.02.2012 - 07:07 Uhr
Sprache: Deutsch
News-ID 114722
Anzahl Zeichen: 8590
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 290 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: WILEX AG: WILEX Inc. appoints Walter Carney as CSO for the further development of Oncogene Science diagnostics"
steht unter der journalistisch-redaktionellen Verantwortung von
WILEX AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
